Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.

RPEP-088102024Mann, Johannes F E; Rossing, Peter; Bakris, George; Belmar, Nicolas; Bosch-Traberg, Heidrun; Busch, Robert; Charytan, David M; Hadjadj, Samy; Gillard, Pieter; Górriz, José Luis; Idorn, Thomas; Ji, Linong; Mahaffey, Kenneth W; Perkovic, Vlado; Rasmussen, Søren; Schmieder, Roland E; Pratley, Richard E; Tuttle, Katherine R

evidence

This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.

Read the original research

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.

Nature medicine, 30(10), 2849-2856

View on PubMed ↗Publisher’s paper ↗

Citation

Mann, Johannes F E; Rossing, Peter; Bakris, George; Belmar, Nicolas; Bosch-Traberg, Heidrun; Busch, Robert; Charytan, David M; Hadjadj, Samy; Gillard, Pieter; Górriz, José Luis; Idorn, Thomas; Ji, Linong; Mahaffey, Kenneth W; Perkovic, Vlado; Rasmussen, Søren; Schmieder, Roland E; Pratley, Richard E; Tuttle, Katherine R. (2024). Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.. Nature medicine, 30(10), 2849-2856. https://doi.org/10.1038/s41591-024-03133-0